The tumor necrosis factor inhibitors adalimumab and infliximab both show good efficacy when used as first biologic agents in patients with refractory uveitis due to Behçet's disease, Spanish research shows.
Approximately half of the 21 patients with juvenile idiopathic arthritis-associated uveitis in the APTITUDE trial experienced an improvement in uveitis assessment with 12 weeks of tocilizumab treatment.
The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.
Decreased cytokine concentrations in the aqueous humour are associated with a response to treatment with anti-vascular endothelial growth factor agents in patients with diabetic macular oedema, study data show.
The Port Delivery System with ranibizumab has the potential to reduce the burden of treatment for patients with neovascular age-related macular degeneration, suggest findings from the phase II Ladder trial.
Treatment with faricimab, a bispecific antibody that targets angiopoietin-2 and vascular endothelial growth factor-A, significantly improves visual acuity versus ranibizumab in patients with diabetic macular oedema, research shows.
Measuring CD11b-positive monocytes could help estimate how many anti-vascular endothelial growth factor injections a patient with neovascular age-related macular degeneration or polypoidal choroidal vasculopathy might need, study findings suggest.
Selective laser trabeculoplasty offers superior intraocular pressure stability to that of eye drops and is more cost-effective when used as a first-line treatment for patients with open angle glaucoma or ocular hypertension, results of the LiGHT trial show.
Both triamcinolone acetonide and bevacizumab improve visual acuity when given as an adjunct to cataract surgery in patients with diabetic macular oedema, but only triamcinolone acetonide results in a sustained anatomical improvement, researchers report.
The degree of nerve fibre layer-focal loss volume and the presence of disc haemorrhage may predict the rate of visual field loss in patients with open angle glaucoma, US researchers report.
Biphasic oxygen targets can decrease the incidence and severity of retinopathy of prematuritywithout increasing the risk of death, cohort study findings suggest.
Retinal nerve fibre layer thinning progresses faster in eyes with lamina cribrosa defects than it does in eyes without such defects, shows an analysis of patients enrolled in the Diagnostic Innovations in Glaucoma Study.
Autologous neurosensory retinal transplantation results in the closure of full thickness macular holes in the vast majority of patients for whom previous surgery has failed, study findings indicate.
Progressive choroidal thinning, as measured by swept-source optical coherence tomography “plays a key role” in the evolution of myopic maculopathy in patients with high myopia, say researchers.
Results of the randomised CANTREAT trial add to increasing evidence that a treat-and-extend ranibizumab regimen results in similar visual outcomes, with fewer injections, than monthly treatment for neovascular age-related macular degeneration.
Statin therapy may reduce the risk of diabetic retinopathy and the need for its associated invasive treatments in patients with type 2 diabetes and dyslipidaemia, population-based study findings indicate.
Researchers have used optical coherence tomography to reveal the development of a fibrosis-like hyper-reflective tissue at the interface between the electronic array and retina in patients who have undergone electronic retinal prosthesis implantation.
The majority of patients with glaucoma appear willing to sign up to receive automated medication reminders linked to their electronic health records, with most describing them as useful, US research shows.
Researchers from the Fight Retinal Blindness! study group have identified a number of variables that predict of sustained loss of visual acuity in patients with neovascular age-related macular degeneration.
Tolerating some subretinal fluid during a treat-and-extend ranibizumab protocol does not detrimentally affect visual acuity in patients with neovascular age-related macular degeneration, study findings indicate.